Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has received good news after a study demonstrated that patients with active Crohn's disease who have ceased responding to Centocor and Schering-Plough's Remicade may respond to Abbott's Humira.
Subscribe to our email newsletter
The study found that 85% of Crohn’s patients who had experienced a reduced or loss of response to Remicade (infliximab) – currently the only FDA-approved biologic treatment for Crohn’s disease – experienced a reduction in disease activity with Humira (adalimumab).
Researchers retrospectively evaluated the safety and efficacy of six months of therapy with Humira in 15 patients with active Crohn’s disease (CD) who experienced a reduced or loss of response to Remicade.
Of the patients who completed the study, 54% had a complete response to treatment with Humira, 31% had a partial response, and 15% were non-responders. Patients with extra-intestinal manifestations of CD (joint pain) improved or resolved their symptoms with Humira treatment, as did one patient who suffered from oral ulcers.
No severe adverse events were observed in this study and there was no evidence of immediate or delayed-type hypersensitivity reactions.